Science Explorer Back to mapMap
Discussion
Institution · GW Pharmaceuticals (United Kingdom)

Most cited papers from GW Pharmaceuticals (United Kingdom)

GW Pharmaceuticals (United Kingdom)

What are the most cited papers from GW Pharmaceuticals (United Kingdom)?

The most cited paper from GW Pharmaceuticals (United Kingdom) is "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy" (Hannah Farmer, Nuala McCabe, Christopher J. Lord et al., 2005), with 6,785 citations. Next come "Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers" (3,663) and "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome" (1,708).

Showing 50 of 59 papers. Every paper with more than 195 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature Apr 2005 6,785
2 Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Peter C.C. Fong, David S. Boss, Timothy Anthony Yap et al. · New England Journal of Medicine Open access 24 Jun 2009 3,663
3 Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome Orrin Devinsky, Judith Helen Cross, Linda Laux et al. · New England Journal of Medicine Open access 24 May 2017 1,708
4 Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects Ethan B. Russo · British Journal of Pharmacology Open access 12 Jul 2011 1,541
5 Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition Nuala McCabe, Nicholas C. Turner, Christopher J. Lord et al. · Cancer Research 15 Aug 2006 1,321
6 ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks Ali Reza Jazayeri, Jacob Falck, Claudia Lukas et al. · Nature Cell Biology 4 Dec 2005 1,071
7 Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome Orrin Devinsky, Anup D. Patel, Judith Helen Cross et al. · New England Journal of Medicine Open access 16 May 2018 1,008
8 Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Orrin Devinsky, Maria Roberta Cilio, Judith Helen Cross et al. · Epilepsia Open access 22 May 2014 1,008
9 Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes Luciano De Petrocellis, Alessia Ligresti, Aniello Schiano Moriello et al. · British Journal of Pharmacology Open access 22 Dec 2010 950
10 Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial Elizabeth Anne Thiele et al. · The Lancet 25 Jan 2018 905
11 A Pathway of Double-Strand Break Rejoining Dependent upon ATM, Artemis, and Proteins Locating to γ-H2AX Foci Enriqueta Riballo, Martin Kühne, Nicole Rief et al. · Molecular Cell Open access Dec 2004 840
12 AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity Christine M. Chresta et al. · Cancer Research 22 Dec 2009 806
13 Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial Philip K. McGuire, Philip Robson, Wiesław Jerzy Cubała et al. · American Journal of Psychiatry Open access 15 Dec 2017 625
14 Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain Jeremy R. Johnson, Mary Burnell-Nugent, Dominique Lossignol et al. · Journal of Pain and Symptom Management Open access 6 Nov 2009 623
15 A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Ethan B. Russo, Geoffrey W. Guy · Medical Hypotheses 5 Oct 2005 616
16 Molecular Targets of Cannabidiol in Neurological Disorders Clementino Ibeas Bih, Tong Chen, Alistair V.W. Nunn et al. · Neurotherapeutics Open access 11 Aug 2015 582
17 Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review John M. McPartland, Marnie Duncan, Vincenzo Di Marzo et al. · British Journal of Pharmacology ReviewOpen access 26 Sep 2014 530
18 Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors Janneke E. Jaspers, Ariena J. Kersbergen, Ute Boon et al. · Cancer Discovery Open access 26 Oct 2012 523
19 A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects Lesley Taylor, Barry E. Gidal, Graham E. Blakey et al. · CNS Drugs Open access 29 Oct 2018 474
20 Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome Orrin Devinsky, Anup D. Patel, Elizabeth Anne Thiele et al. · Neurology Open access 14 Mar 2018 459
21 Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441 Yan Zhao, Huw D. Thomas, Michael A. Batey et al. · Cancer Research Open access 15 May 2006 457
22 Chemistry challenges in lead optimization: silicon isosteres in drug discovery Graham A. Showell, JOHN S. MILLS · Drug Discovery Today Jun 2003 429
23 Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial Russell K. Portenoy, Elena Doina Ganae-Motan, Silvia Allende‐Pérez et al. · Journal of Pain Open access 5 Apr 2012 421
24 Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries Justin J. J. Leahy, Bernard T. Golding, Roger J. Griffin et al. · Bioorganic & Medicinal Chemistry Letters Open access 16 Nov 2004 416
25 Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion Sarah E. Golding, Elizabeth Rosenberg, Nicholas C.K. Valerie et al. · Molecular Cancer Therapeutics Open access Oct 2009 395
26 Early Detection and Differential Diagnosis of Alzheimer’s Disease and Depression with Neuropsychological Tasks Rachel Swainson, J. R. Hodges, Clare J. Galton et al. · Dementia and Geriatric Cognitive Disorders 2001 382
27 Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Jonathan S. Berman, C. Symonds, Rolfe M. Birch · Pain 28 Oct 2004 361
28 Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin Bastiaan Evers, Rinske Drost, Eva Schut et al. · Clinical Cancer Research Open access 15 Jun 2008 336
29 Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation Luciano De Petrocellis, Pierangelo Orlando, Aniello Schiano Moriello et al. · Acta Physiologica 4 Jul 2011 324
30 Cannabis and Cannabis Extracts John M. McPartland, Ethan B. Russo · Journal of Cannabis Therapeutics Jun 2001 321
31 Cannabinoids in the management of difficult to treat pain Ethan B. Russo · Therapeutics and Clinical Risk Management Open access Feb 2008 296
32 Cannabis Systematics at the Levels of Family, Genus, and Species John M. McPartland · Cannabis and Cannabinoid Research Open access Oct 2018 280
33 Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial Orrin Devinsky, Rima Nabbout, Ian Miller et al. · Epilepsia Open access 23 Dec 2018 275
34 Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex Elizabeth Anne Thiele et al. · JAMA Neurology Open access 21 Dec 2020 273
35 Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome Ian Miller, Ingrid Eileen Scheffer, Boudewijn W. Gunning et al. · JAMA Neurology Open access 2 Mar 2020 270
36 Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences J M McPartland, Michelle Glass, Roger G. Pertwee · British Journal of Pharmacology Open access 20 Jul 2007 269
37 Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study Khalid A. Jadoon, Stuart H. Ratcliffe, David A. Barrett et al. · Diabetes Care Open access 29 Aug 2016 262
38 Phytochemical and genetic analyses of ancient cannabis from Central Asia Ethan B. Russo, Hong-En Jiang, Xiao Li et al. · Journal of Experimental Botany Open access Nov 2008 261
39 Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial John T. Farrar, Andrea B. Troxel, Colin G. Stott et al. · Clinical Therapeutics May 2008 260
40 Mutational analysis of the “slippery-sequence” component of a coronavirus ribosomal frameshifting signal Ian Brierley, Alison J. Jenner, Stephen C. Inglis · Journal of Molecular Biology Open access Sep 1992 256
41 The overexpression of specialized DNA polymerases in cancer Mark Robert Albertella, Alan Lau, Mark J. O’Connor · DNA repair 11 Mar 2005 251
42 The medicinal use of cannabis in the UK: results of a nationwide survey Mark A. Ware, Henry E. Adams, Geoffrey W. Guy · International Journal of Clinical Practice Open access 6 Oct 2004 244
43 The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial Douglas Lee Boggs, Toral S. Surti, Aarti Gupta et al. · Psychopharmacology 4 Apr 2018 242
44 Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain Aron H. Lichtman, Eberhard Albert Lux, Robert D. McQuade et al. · Journal of Pain and Symptom Management Open access 18 Sep 2017 237
45 Potency of Δ9–THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology* David J. Potter, Peter I. CLARK, Marc B. Brown · Journal of Forensic Sciences 2008 233
46 Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration Erin L Karschner, William D. Darwin, Robert S. Goodwin et al. · Clinical Chemistry Open access 16 Nov 2010 232
47 Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part I: Design Virgil A. Marple, Daryl L. Roberts, Francisco J. Romay et al. · Journal of Aerosol Medicine Sep 2003 231
48 Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine Ethan B. Russo, Geoffrey W. Guy, Philip Robson · Chemistry & Biodiversity Aug 2007 230
49 Discovery of 4-{4-[(3 R )-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1 H -indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity Kevin M. Foote, Kevin Blades, Anna S. Cronin et al. · Journal of Medicinal Chemistry Open access 11 Feb 2013 217
50 The proposed mechanisms of action of CBD in epilepsy Royston A. Gray, Benjamin J. Whalley · Epileptic Disorders Open access 2020 212

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.